29 March 2017
News and Views
Links and Services
May's issue of the Alimentary Pharmacology & Therapeutics examines the safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation.
The efficacy of rifaximin, a nonsystemic, gut-targeted antibiotic for reducing non–constipation-p
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors